Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

NCT04788043 is registered in ClinicalTrials.gov with Ranjana Advani as lead sponsor.

NCT NCT04788043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04788043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Lead sponsor
Ranjana Advani
Phase
Phase 2
Overall status
Terminated
Start date
June 21, 2022
Completion date
August 29, 2025
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

classic hodgkin lymphoma, hodgkin lymphoma, refractory classic hodgkin lymphoma, relapsed classical hodgkin lymphoma